Literature DB >> 16099452

Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol.

Kenji Hashimoto1, Yuko Fujita, Eiji Shimizu, Masaomi Iyo.   

Abstract

This study was undertaken to examine the effects of subsequent administration of antipsychotic drugs (clozapine and haloperidol) on cognitive deficits in mice after repeated administration of phencyclidine (PCP). In the novel object recognition test, repeated administration of PCP (10 mg/kg) significantly decreased exploratory preference in the retention test session but not in the training test session. PCP-induced deficits were significantly improved by subsequent subchronic (2 weeks) administration of clozapine (5 mg/kg), but not haloperidol (0.1 mg/kg). These findings suggest that PCP-induced cognitive deficits using the novel object recognition test may be a potential animal model of atypical antipsychotic activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16099452     DOI: 10.1016/j.ejphar.2005.07.002

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  40 in total

1.  Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone.

Authors:  Katalin Nagy; Bernadett Marko; Gabriella Zsilla; Peter Matyus; Katalin Pallagi; Geza Szabo; Zsolt Juranyi; Jozsef Barkoczy; Gyorgy Levay; Laszlo G Harsing
Journal:  Neurochem Res       Date:  2010-08-20       Impact factor: 3.996

Review 2.  Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.

Authors:  L Lyon; L M Saksida; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2011-11-10       Impact factor: 4.530

Review 3.  Brexpiprazole: so far so good.

Authors:  Saibal Das; Preeti Barnwal; Blessed Winston A; Somnath Mondal; Indranil Saha
Journal:  Ther Adv Psychopharmacol       Date:  2016-02

4.  Neonatal phencyclidine administration and post-weaning social isolation as a dual-hit model of 'schizophrenia-like' behaviour in the rat.

Authors:  Philip L R Gaskin; Stephen P H Alexander; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

5.  Examination of clozapine and haloperidol in improving ketamine-induced deficits in an incremental repeated acquisition procedure in BALB/c mice.

Authors:  Andrew Nathanael Shen; M Christopher Newland
Journal:  Psychopharmacology (Berl)       Date:  2015-10-29       Impact factor: 4.530

6.  Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.

Authors:  Masakuni Horiguchi; Kayleen E Hannaway; Adesewa E Adelekun; Karu Jayathilake; Herbert Y Meltzer
Journal:  Neuropsychopharmacology       Date:  2012-06-27       Impact factor: 7.853

7.  Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors.

Authors:  Taku Nagai; Rina Murai; Kanae Matsui; Hiroyuki Kamei; Yukihiro Noda; Hiroshi Furukawa; Toshitaka Nabeshima
Journal:  Psychopharmacology (Berl)       Date:  2008-08-06       Impact factor: 4.530

8.  Ethanol and phencyclidine interact with respect to nucleus accumbens dopamine release: differential effects of administration order and pretreatment protocol.

Authors:  Chris Pickering; Pei Pei Chau; Bo Söderpalm; Mia Ericson
Journal:  Front Behav Neurosci       Date:  2010-06-10       Impact factor: 3.558

9.  Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse.

Authors:  Ross Zimnisky; Gloria Chang; István Gyertyán; Béla Kiss; Nika Adham; Claudia Schmauss
Journal:  Psychopharmacology (Berl)       Date:  2012-10-19       Impact factor: 4.530

10.  Pharmacology and therapeutic potential of sigma(1) receptor ligands.

Authors:  E J Cobos; J M Entrena; F R Nieto; C M Cendán; E Del Pozo
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.